For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.03 in the prior trading day, Opus Genetics Inc (NASDAQ: IRD) closed at $2.0, down -1.48%. In other words, the price has decreased by -$1.48 from its previous closing price. On the day, 0.66 million shares were traded. IRD stock price reached its highest trading level at $2.04 during the session, while it also had its lowest trading level at $1.88.
Ratios:
Our goal is to gain a better understanding of IRD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wedbush on October 29, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
On October 16, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $9.
On April 11, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $6.Craig Hallum initiated its Buy rating on April 11, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 26 ’24 when Magrath George bought 100,000 shares for $0.98 per share. The transaction valued at 97,600 led to the insider holds 599,150 shares of the business.
YERXA BENJAMIN R bought 10,000 shares of IRD for $9,834 on Nov 21 ’24. The President now owns 342,800 shares after completing the transaction at $0.98 per share. On Nov 15 ’24, another insider, Magrath George, who serves as the Chief Executive Officer of the company, bought 90,294 shares for $1.01 each. As a result, the insider paid 91,215 and bolstered with 483,244 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRD now has a Market Capitalization of 119816112 and an Enterprise Value of 88387112. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.77 while its Price-to-Book (P/B) ratio in mrq is 6.86. Its current Enterprise Value per Revenue stands at 5.732 whereas that against EBITDA is -2.399.
Stock Price History:
The Beta on a monthly basis for IRD is 0.44, which has changed by 0.7094017 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, IRD has reached a high of $2.37, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 13.20%, while the 200-Day Moving Average is calculated to be 65.03%.
Shares Statistics:
The stock has traded on average 390.43K shares per day over the past 3-months and 661170 shares per day over the last 10 days, according to various share statistics. A total of 59.91M shares are outstanding, with a floating share count of 24.94M. Insiders hold about 56.48% of the company’s shares, while institutions hold 23.68% stake in the company. Shares short for IRD as of 1760486400 were 308958 with a Short Ratio of 0.79, compared to 1757894400 on 90128. Therefore, it implies a Short% of Shares Outstanding of 308958 and a Short% of Float of 0.54.
Earnings Estimates
The dynamic stock of Opus Genetics Inc (IRD) is currently being evaluated by a team of 1.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.6 and -$0.6 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.4, with 1.0 analysts recommending between -$0.4 and -$0.4.
Revenue Estimates
6 analysts predict $3.08M in revenue for. The current quarter. It ranges from a high estimate of $4M to a low estimate of $2.5M. As of. The current estimate, Opus Genetics Inc’s year-ago sales were $3.87MFor the next quarter, 6 analysts are estimating revenue of $3.42M. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 6 analysts have provided revenue estimates for IRD’s current fiscal year. The highest revenue estimate was $15.25M, while the lowest revenue estimate was $12.25M, resulting in an average revenue estimate of $13.77M. In the same quarter a year ago, actual revenue was $10.99MBased on 6 analysts’ estimates, the company’s revenue will be $17.55M in the next fiscal year. The high estimate is $30M and the low estimate is $8M.
